Skiplinks


Breadcrumb

IQWiG reports

 

unknown translation: [en, texteInc, filter_publication]

Selected values All


Page 1

1549 Results (on 78 pages)
Show results on one page
No. ^v Title ^v Report type Published ^v Size
A17-27Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) (German version)Extract of dossier assessment2017-09-1578 kB, PDF Project
A17-27Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) (German version)Dossier assessment2017-09-15855 kB, PDF Project
G17-04Blinatumomab (acute lymphoblastic leukaemia)- Assessment according to §35a (para. 1., sentence 10) Social Code Book V (expiry of the decision) (German version)Dossier assessment2017-09-15160 kB, PDF Project
V16-03Search for guidelines for the update of the DMP “coronary heart disease” (German version)Preliminary report2017-09-116 MB, PDF Project
A17-23Pembrolizumab (classical Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V (German version)Extract of dossier assessment2017-09-0131 kB, PDF Project
A17-23Pembrolizumab (classical Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V (German version)Dossier assessment2017-09-01264 kB, PDF Project
A17-24Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V (German version)Extract of dossier assessment2017-09-0187 kB, PDF Project
A17-24Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V (German version)Dossier assessment2017-09-012 MB, PDF Project
A17-26Rolapitant (prevention of nausea and vomiting in chemotherapy) - Benefit assessment according to §35a Social Code Book V (German version)Extract of dossier assessment2017-09-0147 kB, PDF Project
A17-26Rolapitant (prevention of nausea and vomiting in chemotherapy) - Benefit assessment according to §35a Social Code Book V (German version)Dossier assessment2017-09-01603 kB, PDF Project
A17-25Etelcalcetide (secondary hyperparathyroidism) - Benefit assessment according to §35a Social Code Book V (German version)Extract of dossier assessment2017-09-0162 kB, PDF Project
A17-25Etelcalcetide (secondary hyperparathyroidism) - Benefit assessment according to §35a Social Code Book V (German version)Dossier assessment2017-09-01358 kB, PDF Project
A17-30Ixekizumab (plaque psoriasis) - Addendum to Commission A17-07 (German version)Addendum to Commission A17-072017-08-17268 kB, PDF Project
A17-31Secukinumab (plaque psoriasis) - Addendum to Commission A17-08 (German version)Addendum to Commission A17-082017-08-1791 kB, PDF Project
S16-05Screening for depression (German version)Report plan2017-08-14206 kB, PDF Project
S16-05[S16-05] Screening for depression - timetable2017-08-1441 kB, PDF Project
N16-02Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failure (German version)Preliminary report2017-08-082 MB, PDF Project
A17-28Pembrolizumab (non-small cell lung cancer) - Addendum to Commission A17-06 (German version)Addendum to Commission A17-062017-08-04149 kB, PDF Project
A17-19Alectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V (German version)Extract of dossier assessment2017-08-0155 kB, PDF Project
A17-19Alectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V (German version)Dossier assessment2017-08-01579 kB, PDF Project

Page 1

1549 Results (on 78 pages)
Show results on one page
to top

Glossary entries